The AscencioDx proprietary platform will enable rapid product development for new viral and bacterial targets. Credit: Anavasi Diagnostics / Business Wire.

NIH/RADx-funded medical technology firm Anavasi Diagnostics has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for The AscencioDx Covid-19 Test and The AscencioDx Molecular Detector.

Anavasi has developed its new test for the identification of SARS-CoV-2 RNA to deliver a result within 20 minutes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Covid-19 test deploys assay chemistry to target several locations on the viral genome, thereby minimising the likelihood of missing a new strain.

The AscencioDx system has been designed to facilitate point-of-care molecular testing in different healthcare environments, including facilities such as mobile testing sites, urgent care centres and assisted nursing care centres.

Furthermore, the platform will allow quick product development for new viral and bacterial targets, such as influenza, RSV and sexual health-related strains.

See Also:

Anavasi Diagnostics president and CEO Nelson Patterson said: “Accurate, quick, and affordable molecular testing remains the greatest need for Covid testing today.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The AscencioDx Covid-19 Test covers 99.99% of all Omicron variants as well as prior variants of concern. Users in our clinical trial sites appreciated its speed, reliability and ease of use.

“AscencioDx will be a pivotal platform for future diagnostics. We never want to lose sight of the goal that everyone deserves access to high quality, highly accurate, affordable diagnostic tests.”

Similar to more expensive polymerase chain reaction (PCR) testing, the AscencioDx Molecular Detector design uses reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology and avoids sending samples to a different location.

Furthermore, the test and detector are said to create less bio waste, as the detector is reusable for at least 3,000 test cycles.